Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4382432 | 0.84 | CYP1A2 (0.33) | CYP1A2CHRM3 | |
| SCHEMBL25453177 | 0.82 | PSEN1 (0.38) | CYP1A2CHRM3 | |
| SCHEMBL13910201 | 0.82 | PSEN1 (0.38) | CYP1A2CHRM3 | |
| SCHEMBL18965497 | 0.82 | PSEN1 (0.38) | CYP1A2CHRM3 | |
| SCHEMBL4381935 | 0.81 | PKM (0.41) | CYP1A2CHRM3 | |
| SCHEMBL22473381 | 0.81 | PKM (0.41) | CYP1A2CHRM3 | |
| SCHEMBL4381929 | 0.81 | CYP1A2 (0.35) | CYP1A2CHRM3 | |
| SCHEMBL22388304 | 0.81 | CYP1A2 (0.35) | CYP1A2CHRM3 | |
| SCHEMBL13337091 | 0.81 | CYP1A2 (0.35) | CYP1A2CHRM3 | |
| SCHEMBL3124831 | 0.81 | CYP1A2 (0.35) | CYP1A2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | claimed |
| EP-1119567-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-05-04 | — | — | EP | claimed |
| CN-1161352-C | Quinazoline derivatives | — | 2004-08-11 | — | — | CN | claimed |
| CN-1322202-A | Quinazoline derivatives | ASTRA ZENECA N V (SE) | 2001-11-14 | — | — | CN | claimed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | claimed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | claimed |
| US-8492560-B2 | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2013-07-23 | — | — | US | disclosed |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | STOKES ELAINE S E (GB) | 2012-08-02 | — | — | US | disclosed |
| EP-2050744-A1 | Quinazoline derivatives as angiogenesis inhibitors | AstraZeneca AB (SE) | 2009-04-22 | — | — | EP | disclosed |
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | HENNEQUIN LAURENT FRANCOIS ANDRE | 2008-12-18 | — | — | US | disclosed |
| US-7371765-B2 | Quinoline derivatives having VEGF inhibiting activity | ASTRAZENECA AB (SE) | 2008-05-13 | — | — | US | disclosed |
| CN-100360505-C | Quinazoline derivatives as angiogenesis inhibitors | ASTRAZENECA AB (SE) | 2008-01-09 | — | — | CN | disclosed |
| US-7262201-B1 | For the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals | ASTRAZENECA AB (SE) | 2007-08-28 | — | — | US | disclosed |
| WO-2002012226-A1 | QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| WO-2002012228-A1 | CINNOLINE COMPOUNDS | ASTRAZENECA AB (SE) | 2002-02-14 | — | — | WO | disclosed |
| EP-1154774-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | AstraZeneca AB (SE) | 2001-11-21 | — | — | EP | disclosed |
| CN-1322202-A | Quinazoline derivatives | ASTRA ZENECA N V (SE) | 2001-11-14 | — | — | CN | disclosed |
| EP-1119567-A1 | QUINAZOLINE DERIVATIVES | AstraZeneca AB (SE) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000047212-A1 | QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000021955-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2000-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312273-A1 | Quinoline Derivatives Having Vegf Inhibiting Activity | VEGFA, FLT1, FLT4 | CYP1A2 1059/4885CHRM3 1965/4885 |
| US-20120197027-A1 | Quinazoline Derivatives as Angiogenesis Inhibitors | VEGFA, FLT1, KDR | CYP1A2 807/4885CHRM3 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.